FIELD: medicine.
SUBSTANCE: group of inventions relates to a compound for the treatment of diseases or disorders related to pathological calcification or pathological ossification. Soluble fused polypeptide of ectonucleotide of pyrophosphatase/phosphodiesterase-1 (ENPP1) of the formula: PROTEIN-Z-DOMAIN is proposed, where PROTEIN contains 23-849 residues from SEQ ID NO: 20, 23-852 residues from SEQ ID NO: 18 or 93-925 residues from SEQ ID NO: 16; DOMAIN contains human Fc IgG1 domain; and Z is an amino acid sequence selected from SEQ ID NO: 28-30; where polypeptide lacks a negatively charged bone-targeted domain and is enzymatically active. A cell and a method for producing the specified soluble fused polypeptide of ectonucleotide of pyrophosphatase/phosphodiesterase-1 (ENPP1), and its application in a pharmaceutical composition are also proposed.
EFFECT: injection of this polypeptide increases extracellular concentrations of pyrophosphate (PPi), thus, reducing or preventing calcification of heart and/or arteries.
16 cl, 10 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| NPP1 FUSION PROTEINS | 2011 |
|
RU2760943C2 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| INSECTICIDE PROTEINS OF PLANT ORIGIN AND THEIR APPLICATION METHODS | 2016 |
|
RU2762832C2 |
| ISOLATION OF A NEW PESTIVIRUS CAUSING CONGENITAL TREMOR A | 2017 |
|
RU2765658C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| IL4/IL13 RECEPTOR MOLECULE FOR VETERINARY USE | 2018 |
|
RU2795591C2 |
| FUSED MOLECULES DERIVED FROM CHOLIX-TOXIN FOR ORAL DELIVERY OF BIOLOGICALLY ACTIVE LOADS | 2015 |
|
RU2723178C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| POLYVALENT AND POLYSPECIFIC OX40-BINDING FUSED PROTEINS | 2017 |
|
RU2773052C2 |
